JUNS Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and in…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
Weekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Aurora Cannabis Urged Shareholders to Reject Curaleaf’s Hostile Takeover Bid Tilray Expanded Global Cannabis Production as International Medical Demand Continues to Grow Key Takeaways; Psychedelic Sector Jupiter Neurosciences Raised $2 Million as the Company Advances its Parkinson’s Drug Program Optimi Health Secured Discretionary Equity Facility as Psychedelic Drug Business Expands SciSparc […] | ||
US Equity Indexes Rise Despite Surging Bond Yields as US Nears Tariff Deal With Canada US equity indexes rose markedly on Friday, even as bond yields continued to rise after Canada's trad | ||
US Equity Indexes Rise Despite Surging Bond Yields US equity indexes rose markedly ahead of the close on Friday after a sharp selloff in the previous s | ||
 Real Parkinson’s Disease Hope from Jupiter Neurosciences By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge. | ||
 Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […] | ||
 Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) The exclusive U. S. licensing deal adds a second clinical-stage CNS asset to Jupiter Neurosciences’ pipeline, expanding its development strategy beyond its lead Parkinson’s disease program. | ||